NMTC NEUROONE MEDICAL TECHNOLOGIES CORP

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time

EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025.

Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Thursday, May 14, 2025, to discuss the Company’s third quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Third Quarter 2025 Earnings Conference Call

Date: Thursday, August 14, 2025

Time: 8:30 a.m. Eastern time

U.S. Dial-In (Toll Free): 888-506-0062

International Dial-In: 973-528-0011

Participant Access Code: 939482

Webcast:

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through Thursday, August 28, 2025. To listen, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 52598. A webcast replay will also be available using the webcast link above through August 28, 2025.

About NeuroOne

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit .

IR Contact

MZ Group – MZ North America



EN
31/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUROONE MEDICAL TECHNOLOGIES CORP

 PRESS RELEASE

NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ab...

NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received U.S. Food and Drug Administration (“FDA”) clearance to market its One...

 PRESS RELEASE

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Re...

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the third quarter of fiscal year 2025 ended June 30, 2025. Recent Company...

 PRESS RELEASE

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results o...

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:3...

 PRESS RELEASE

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results o...

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Ea...

 PRESS RELEASE

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent...

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office (USPTO) titled, “Methods for Making Probe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch